Cidara Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Cidara Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Cidara Therapeutics Inc
Rating: 1.81633325
Author: Trendlyne DVM scores

about

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprise...

64.93 1.50 (2.36%)

540.34% Gain from 52W Low

242.9K

XNAS Volume

XNAS 04 Sep, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

2.3 / 100

Technically Bullish

70.3 / 100

1Yr Price target upside is 23%

5 analysts

Cidara Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Cidara Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprise...

540.34% Gain from 52W Low

SWOT Analysis

Cidara Therapeutics Inc Live Price Chart